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with regard to in vitro resistance, SCCmec type, frequency of pvl
gene and MLST type.
There have rare report about molecular characteristic of CA-
MRSA infections in children from China, this prospective study
was undertaken in order to characterize the molecular char-
acteristic of CA-MRSA in children in China. We collected 99
CA-MRSA isolates from 8 hospitals in 7 cities in China between
2008 and 2009. All isolates were analysed by a combination of
different genotyping methods, including MLST, SCCmec type, and
spa typing, pvl gene was also detected.
In all of the CA-MRSA isolates, twelve STs were obtained, and
ST59 (58.6%) was the most prevalent type throughout China.
SCCmec type IV (67.7%) was the most popular type, and sub-
types IVa, IVc, IVg were found in 77.6%, 11.9%, 2.9% of those
isolates respectively. Eleven spa types were identiﬁed, and four
new spa types were ﬁrstly registered on the net in our ﬁndings.
ST59-SCCmec IVa with t437, was the most prevalent clone. In
addition, 57.6% of those isolates were PVL positive. CA-MRSA iso-
lates were found to be resistant to non-β-lactam antimicrobial,
and multidrug resistance was observed in 85.9% of them.
In conclusion, the recent increase in CA-MRSA infections in
children of China is largely associated with the spread of the
ST59-SCCmec IVa with t437 clone and the multiresistant rate is
high.
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Fibrosis is a frequent, life-threatening complication of most
chronic liver diseases. Up to now liver biopsy is still the gold stan-
dard for assessment of hepatic ﬁbrosis and cirrhosis. However, it
is invasive with possible complications, costly and afﬂicted with
a high degree of sampling error. There is a strong demand for
reliable, liver speciﬁc, non-invasive biomarkers of ﬁbrosis and
cirrhosis to replace or to complement the invasivemethod of nee-
dle biopsy. Class I biomarkers are deﬁned as serum components
which reﬂect ECM turnover (ﬁbrogenesis and ﬁbrolysis) and ﬁ-
brogenic cell changes, mainly of hepatic stellate cells, which are
the dominant proﬁbrogenic cell type in liver. The development of
hepatic ﬁbrosis or cirrhosis is due to increased synthesis, depo-
sition, and possibly reduced degradation of hepatic extracellular
matrix components, especially collagens, such as interstitial type
I and III, basement membrane type IV, microﬁbrillar type VI, and
pericellular type V, non-collagenous proteins, such as laminin,
ﬁbronectin, undulin, etc. Class II biomarkers comprise in general
rather simple standard laboratory tests, which are grouped into
panels. Class II biomarkers are based on algorithmic evaluation
of commonly observed functional alterations of the liver that
do not necessarily reﬂect ECM metabolism and/or ﬁbrogenic
cell changes. About 20 numerical scores or indices are reported
for parameters, which are mostly routine laboratory tests and
frequently multiparametric (panels). They fulﬁl most criteria for
detection and staging of ﬁbrosis and to a lesser extent grading of
ﬁbrogenic activity. The Fibrotest is the most investigated com-
bination of serum markers for ﬁbrosis. However, the diagnostic
use of many of these scores is still limited and standardization
of the assays is only partially realized. Transient elastography
(Fibroscan), which measures the stiffness of the liver by means
of ultrasound as a measure of ﬁbrosis and cirrhosis, is simple to
perform and the inter- and intra-observer variability is small. The
accuracy is high in discriminating between cirrhosis and ﬁbrosis,
but lower for discriminating between the different stages of
ﬁbrosis in both chronic hepatitis B and C. All the makers of liver
ﬁbrosis can be combined for a better diagnosis.
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Background: Spontaneous bacterial peritonitis (SBP) is a major
cause of morbidity and mortality in cirrhosis patients. Gram neg-
ative bacilli, such as Escherichia coli and Klebsiella species (EK)
are the most common cause of SBP. Recently, infections due to
antibiotic-resistant microorganism have increased, especially by
extended-spectrum β-lactamase-producing EK (ESBL-EK). How-
ever, among SBP in patients with advanced liver cirrhosis, the
impacts of antibiotic-resistant (including ESBL-producing) organ-
isms on clinical outcome and risk factors for infection have not
been well focused.
Aims & Methods: Electronic searches in MEDLINE and EMBASE
about SBP in patients with advanced liver cirrhosis were per-
formed to elucidate clinical implications of SBP due to antibiotic-
resistant microorganism.
Results: SBP due to microorganism which was resistant to third
generation cephalosporin accounted for 5∼15%. SBP due to
antibiotic-resistant organism had poorer outcome than SBP by
antibiotic-susceptible strain. Especially, 30-day mortality of SBP
due to ESBL-EK was very high (about 50%). And the risk factors for
the development of infection with antibiotic-resistant organisms
that have been listed in several studies are: underlying severe
hepatic dysfunction, nosocomial infection, longer hospital stay
and ICU stay, presence of indwelling vascular catheter, prior
administration of an antibiotic and higher severity of illness.
Although the impact of a delay in effective initial treatment
was controversial, several studies suggest that ineffective initial
therapy may be a cause of the higher mortality.
Conclusions: SBP due to antibiotic-resistant organism had higher
mortality than SBP by susceptible strain and ineffective initial
therapy may be a cause of the higher rates of treatment failure
and mortality. Therefore, it would seem reasonable to treat
patients with SBP due to antibiotic-resistant organism with ef-
fective antibiotics straight away. However, the injudicious use of
broad antimicrobial regimens is likely to result in further emer-
gence of resistance. To promote the prudent use of antimicrobial
agents, we need further efforts to identify the risk factors for
antibiotic-resistant infection.
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The introduction of the 7-valent (types 4, 6B, 9V, 14, 18C, 19F
and 23F) pneumococcal conjugate vaccine has brought a signif-
icant reduction in invasive pneumococcal disease in the United
States and Europe. In the ≤ 2 years old, the incidence of pneu-
mococcal bacteraemia has decreased from 188 to 59/100,000
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cases from 1998/9 to 2001, whilst among all age group, the
incidence dropped from 24.3 to 17.3/100,000 cases. A change
in antibiotic resistance rates, such that macrolide resistance in
invasive pneumococcal disease, fell from 9.3 to 2.9 per 100,000
population in Atlanta, US, has been observed.
Pneumococci are “inhabitants” of the oral ﬂora and colonizes
the nasopharynx, particularly in young children. A recent study
showed that nasopharyngeal carriage has been replaced by the
appearance in frequency of drug-resistant S. pneumoniae (DRSP)
expressing unusual serotypes (6A, 10A, 15A, 15C, 19A, 23A, 33F)
not present in the vaccine, as well as an increase in nontypeable
strains. These nontypeable and “atypical” pneumococci may
become more apparent in the clinical laboratory and be prob-
lematic in identiﬁcation. “Atypical” strains lack one or more of
the deﬁning characteristics of pneumococcus, namely, optochin
(OPT) susceptibility, bile solubility and agglutination with antip-
neumococcal polysaccharide capsule antibodies. Controversial
results also occur from the DNA-based methods for identiﬁcation
of pneumococci. “Atypical” S. pneumoniae has been implicated
in a number of outbreaks of infections in the U.S. and in serious
lower respiratory tract infections, whilst ‘variants’ closely re-
lated to the mitis group have also led to major outbreaks of toxic
shock-like syndrome in China.
A preliminary study indicated 9% of non-typeable S. pneumoniae
from Asian countries were identiﬁed as “atypical” isolates with
incompatible phenotypic and genotypic characteristics, suggest-
ing that this may not be uncommon in Asian countries where
DRSP is prevalent and subjected to intense antibiotic pressure.
S. pneumoniae is undergoing tremendous selective pressure for
capsular switching and interspecies transfer. The introduction of
the protein conjugate vaccine will likely create stronger evo-
lutionary impact to the pneumococcal population, altering its
epidemiology, serotype distribution and prevalence of antibiotic
resistance.
CS18-02 Pneumococcal Diseases Burden in Asia
Lulu C. Bravo*. University of the Philippines Manila
Pneumococcal disease kills about 2 million every year in the
world today, half of which are children less than 5 years of age
more than 95% are in developing countries of Asia and Africa.
WHO estimates that of those dying from pneumonia, 50% are due
to pneumococcal disease, 20% from H inﬂuenza and the rest from
other bacterial and viral etiologic agents. It is also estimated that
for every 100 pneumonia cases, there will be 10 septicemia and
1 meningitis case as the frequency distribution of invasive pneu-
mococcal disease or IPD. The non-invasive cases are mostly in the
form of otitis media which is considered the most frequent cause
of Out-patient consultation. In both developed and developing
world, otitis media has been a constant cause of hospitalization
and frequent antibiotic therapy with complications of recurrent
otitis media and chronic otitis media that may lead to hearing
loss and learning disabilities.
Streptococcus pneumonia is a highly encapsulated organism,
whose antigenic properties are characterized by more than
90 serotypes, not all of which cause disease but only a few
are highly pathogenic and resistant to antibiotics. Different
geographic locations have been found to have different predomi-
nating serotypes and this has been the basis for surveillance and
continued monitoring of the presently predominating serotypes.
It has also been shown that the incidence of pneumococcal
disease differs from region to region and in different population
and ethnic groups. There has also been reports of the presence
of possible increase in certain serotypes during certain parts of
the year implying the possibility of outbreak characteristics of
this organism and could also be attributed to antibiotic pressure.
In Asia, there is in general a lack of data regarding the inci-
dence and the types of pneumococcal disease predominating
in the countries. It is only recently that Asians are beginning
to become aware of pneumococcal disease with the entry of
information on the impact of pneumococcal conjugate vaccine in
USA and Europe.The lack of awareness on pneumococcal disease
is brought about by non-recognition of the speciﬁc pathogen
due to the difﬁculty of isolating the organism and the limited
resources of blood cultures and other laboratory techniques for
identifying it. Since the invasive form of the disease presents the
same way as other organisms such as H inﬂuenza, Streptococcus
pyogenes, Salmonella, Neisseria meningitides or even some viral
pathogens, the diagnosis of pneumococcal disease has not been
an important part of the medical management among Asian hos-
pitals except for a few industrialized countries.Thus there is very
little awareness of pneumococcal disease in Asia.
With the deaths from Pneumococcal Disease considered by WHO
now as the #1 vaccine-preventable deaths in children today, it is
necessary that countries in Asia begin to acknowledge the valu-
able contribution that pneumococcal conjugate vaccine can do
for the achievement of MDG4 and improvement of child survival.
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Streptococcus pneumoniae is the major cause of life-threatening
invasive diseases, including meningitis, septicaemia and pneumo-
nia. The rapid emergence of multidrug-resistant pneumococcal
strains throughout the world is leading to increased emphasis on
the prevention of pneumococcal infections by vaccination. The
emerging and potential shortcomings of current polysaccharide-
based vaccines prompt researchers to develop a new generation
of pneumococcal vaccines. In the past ﬁve years, we evalu-
ated the protective efﬁcacy of immunizing mice with different
pneumococcal surface protein antigens in invasive-diseasemouse
models, and protection against invasive challenge with 12 dif-
ferent serotypes of S. pneumoniae was assessed in two murine
strains. In addition, we established a functional in vitro assay
to measure the bactericidal activity of antibodies. Our ﬁndings
ﬁrstly demonstrated that active immunization with ClpP and
passive immunization with antibodies speciﬁc for ClpP could
elicit serotype-independent protection against pneumococcal in-
fection, and a mixture of pneumococcal protein antigens (ClpP,
CbpA, and PspA) could further enhance this protection. Anti-
ClpP, anti-CbpA or anti-PspA hyperimmune sera from immunized
mice could signiﬁcantly inhibit the adhesion of Streptococcus
pneumoniae to A549 cells and combination of them resulted in
an additive effect. All antisera could also kill S. pneumoniae
by polymorphonuclear leukocytes in a complement-dependent
way. The anti-infection activity and production of hyperimmune
antibodies induced by immunization with pneumococcal protein
antigens could be abrogated by the depletion of CD4+ T lympho-
cytes. Taken together, our observations provided evidence that
immunization with the mixture of different pneumococcal sur-
face proteins could protect against Streptococcus pneumoniae
more efﬁciently, suggesting that immunization with the combina-
tion of selected pneumococcal virulence proteins is an applicable
way to achieve effective protection against pneumococcal infec-
tion. Our future studies include evaluating protection effects
by the way of combining other promising pneumococcal protein
antigens using different adjuvants in other animal models in
order to ﬁnd out the best formulation of pneumococcal protein
vaccines.
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